TLR7/8 agonist 9 structure
|
Common Name | TLR7/8 agonist 9 | ||
|---|---|---|---|---|
| CAS Number | 2649170-17-0 | Molecular Weight | 366.46 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H26N6O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TLR7/8 agonist 9TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC50s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has anti-tumor activity and improves the antitumor activity of PD-1/PD-L1 blockade. TLR7/8 agonist 9 can be used for research of cancer immunotherapy[1]. |
| Name | TLR7/8 agonist 9 |
|---|
| Description | TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC50s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has anti-tumor activity and improves the antitumor activity of PD-1/PD-L1 blockade. TLR7/8 agonist 9 can be used for research of cancer immunotherapy[1]. |
|---|---|
| Related Catalog | |
| Target |
EC50s: 40 nM and 23 nM for hTLR7/8[1] |
| References |
| Molecular Formula | C20H26N6O |
|---|---|
| Molecular Weight | 366.46 |